Elobixibat is a medication used to treat chronic constipation. During the manufacturing process, impurities may be introduced into the drug substance or drug product. These impurities can affect the safety and efficacy of the medication, and must be monitored and controlled during production. Some of the potential impurities in elobixibat include related compounds, residual solvents, and degradation products. Analytical methods are used to identify and quantify these impurities, and strict limits are set to ensure the
![(2-(2-((3,3-dibutyl-7-(mercapto)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetamido)-2-phenylacetyl)glycine](https://clearsynth.com/structure/-2--2---3-3-dibutyl-7--mercapto--1-1-dioxido-5-phenyl-2-3-4-5-tetrahydrobenzo-b--1-4-thiazepin-8-yl-oxy-acetamido--2-phenylacetyl-glycine.png "Elobixibat Impurities")
